MIRA INFORM REPORT

 

 

Report Date :

27.07.2012

 

IDENTIFICATION DETAILS

 

Name :

TAI YU CHEMICAL & PHARMACEUTICAL CO., LTD.

 

 

Registered Office :

No.1, Alley 13, Lane 11, Yun San Rd., Chu Tung Hsinchu

 

 

Country :

Taiwan

 

 

Date of Incorporation :

20.11.1973

 

 

Com. Reg. No.:

47066452

 

 

Legal Form :

Joint Stock Company

 

 

Line of Business :

Manufacturing and sales of medicinal chemicals, botanical drugs and herbs

 

 

No. of Employees :

About 200 Employees

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Taiwan

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


Contact Points

 

Company Name:

Tai Yu Chemical & Pharmaceutical Co., Ltd.

Supplied Name:

Tai Yu Chemical & Pharmaceutical Co Ltd.

Trading Address:

No.1, Alley 13, Lane 11, Yun San Rd., Chu Tung Hsinchu Taiwan

Supplied Address:

1 Alley 13 Lane 11 Yun san Rd Chutung Chen Hsinchu Hsien 310 Taiwan

Telephone Number:

+886-3-582-6655

Fax Number:

+886-3-582-2389

E-mail:

taiyu3@ms.69.hinet.net; taiyu.act@msa.hinet.net

Notes: The exact address is as above.

 

Credit Summary

 

Credit Opinion:

Business connections are permissible.

 

Company Identification Details

 

Registered Name:

Tai Yu Chemical & Pharmaceutical Co., Ltd.

Registered Address:

No.1, Alley 13, Lane 11, Yun San Rd., Chu Tung Hsinchu Taiwan

Date of Foundation:

1973-11-20

Registration Number:

47066452

Registry:

MOEA Central Office

Registered Capital:

NTD 367,700,000 (USD 12,281,180)

(As of 2012.07, 1 NTD = 0.0334 USD)

Paid-up Capital:

NTD 245,960,000 (USD 8,215,064)

Legal Representatives:

Shanjie Lin

Legal Form:

Joint Stock Company

Principal Activities:

Manufacturing and sales of medicinal chemicals, botanical drugs and herbs

Staff:

About 200 Employees

Listed at Stock Exchange:

No

Date of Last Annual Return:

2011-12-5

 

History

 

Subject was incorporated on 1973-11-20 with registered number 47066452 as Joint Stock Company in Taiwan.

 

Shareholders

 

Name

Subscription Shares

Shanjie Lin

10,070

Peiling Lin

3,300

 

The information above is that of subject’s major shareholders.

 

Subsidiaries & Branches

 

Related Companies

1

Name

Hua Yu (Wu Xi) Pharmaceutical Co., Ltd

Address

43 Mashan Mei Liang Road, Binhu District, Wuxi City, Jiangsu Province, China

2

Name

Tai Yu (Wu Xi) Pharmaceutical Co., Ltd

Address

No 1, 43 Mashan Mei Liang Road, Binhu District, Wuxi City, Jiangsu Province, China

 

Personnel Information

Core Management

 

Directors

1

Name

Shanjie Lin

Position

Chairman

2

Name

Jinlian Xu

Position

Director

3

Name

Yanming Zheng

Position

Director

4

Name

Peiling Lin

Position

Supervisor

 

Personnel Structure

 

Total Employees

About 200 Employees

 

Operation Information

 

Offices & Factories

 

 

Headquarters

Add

No.1, Alley 13, Lane 11, Yun San Rd., Chu Tung Hsinchu Taiwan

 

 

Production Information

 

l         Subject is engaged in manufacturing of medicinal chemicals, botanical drugs and herbs, etc.

l         It is introduced that subject’s Taiwan factory is about 10,000 square meters.

 

Purchase Information

 

l         The registered activities of subject:

Business Code

Details

C110010

Manufacturing of drink

C199990

Manufacturing of other uncategorized food

C801030

Manufacturing of precision chemical materials

C802041

Manufacturing of western medicine

C802060

Manufacturing of animal medicine

C802100

Manufacturing of cosmetic

C802990

Manufacturing of other chemical

CF01011

Manufacturing of medical device

F102040

Wholesale of drink

F102170

Wholesale of food and groceries

F107990

Wholesale of other chemical

F108021

Wholesale of western medicine

F108031

Wholesale of medical device

F108040

Wholesale of cosmetic

F203010

Retail of food, drink and groceries

F207990

Retail of other chemical

F208021

Retail of western medicine

F208031

Retail of medical device

F208040

Retail of cosmeticness

F401010

International trade business

ZZ99999

Besides licensed business, all other business items those are not banned or restricted.

 

l         The raw materials for production are purchased from both home and abroad.

 

 

Sales Information

 

l         Subject is engaged in sales of medicinal chemicals, botanical drugs and herbs, etc.

l         Subject’s major customers are hospital and clinic, etc.

l         Subject’s products are mostly sold in Taiwan domestic market.

l         Subject obtained the certification of GMP.

Major products sold

 

Product

1

Antibiotics (Penicillins, Cephalosporins, Aminoglycosides, Other Antibiotics)

2

Antibacterial Agents

3

Antipyretics Analgesics & Anti-inflammatories

4

Antigout Agents

5

Adrenocortical Hormones

6

Antitussives Expectorants & Antiasthmatics

7

Common Cold preparations

8

Antihistamine Agents

9

Vitamins

10

Hepatotonics & Antidotes

11

Antihypertensive Agents

12

Cardiotonics & Diuretics

13

Anti-dizziness Agents

14

Cerebral Metabolic Agents

15

Spasmolytics

16

Remedies of Peptic Ulcer

17

Gastrointestinal Agents

18

Antiemetics

19

Hemostatic Agents

20

Autonomic Agents

21

Anti-Diabetic Agents

22

Hormone Preparations

23

Oxytocics

24

Water, Nutrients and Electrolytes

25

Metabolics & Electrolytes

26

Local Anesthetics

27

Dermatics

 

Import and export right:

Import right

Yes

Export right

Yes

 

Settlements

 

Purchase

 

Domestic Purchase (Taiwan and Mainland, China)

Product

Payment Terms

Proportion

Raw materials

COD, CBD, etc

100%

 

Foreign Purchase

Product

Payment Terms

Proportion

Raw materials

CBD, etc

100%

Sales

 

Domestic Markets (Taiwan and Mainland, China)

Product

Sales Terms

Proportion

Medicinal chemicals and drugs

COD, CBD, etc

100%

 

Export

Product

Sales Terms

Proportion

Medicinal chemicals and drugs

CBD, etc

100%

Notes: Subject’s settlement for export is generally in USD

 

Financial Information

 

Subject has no obligations to disclose its financial statements to the third party according to the relevant policy in Taiwan and the only source from which we can obtain the information is the subject itself.

Subject’s relevant staff Mr. Zhang declined to disclose its financials citing the grounds of company’s confidentiality; from other source we can not obtain the relevant information, either.

 

Bankers

 

Name

Taipei Bank

 

Public Record

 

Mortgage

 

No chattel mortgage record of subject has been found within the recent 3 months.

 

Lawsuit

 

Up to date of reporting, no existing or latent litigation of the subject has been found.

 

Interview Details

 

Name

Mr. Zhang

Department

Sales Department

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.55.95

UK Pound

1

Rs.86.56

Euro

1

Rs.67.95

 

 

INFORMATION DETAILS

 

Report Prepared by :

PRL

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.